Edoxaban for venous thromboembolism treatment—the new kid on the block for Latin America. A practical guide

E Ramacciotti, VCR Aguiar, VC Júnior… - Clinical and Applied …, 2018 - journals.sagepub.com
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC)
approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin …

Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial

C Dziri, W Ben Hmida, W Dougaz, M Khalfallah… - Plos one, 2023 - journals.plos.org
Cancer and/or major surgery are two factors that predispose to post-operative thrombosis.
The annual incidence of venous thromboembolic disease (VTED) in cancer patients was …

Comparative studies on the anticoagulant profile of branded enoxaparin and a new biosimilar version

D Qneibi, E Ramacciotti, AS Macedo… - Clinical and Applied …, 2020 - journals.sagepub.com
Low molecular weight heparins (LMWH) represent depolymerized heparin prepared by
various methods that exhibit differential, biochemical and pharmacological profiles …

Safety and effectiveness of biosimilar enoxaparin (Inhixa) for the prevention of thromboembolism in medical and surgical inpatients

C Fantoni, L Bertù, EM Faioni, C Froiio… - Internal and emergency …, 2021 - Springer
In 2016, biosimilar enoxaparin (Inhixa®, Techdow) was introduced in European markets
with the same indications as branded enoxaparin (Clexane®, Sanofi). Its use is constantly …

[PDF][PDF] HEPARINAS DE BAJO PESO MOLECULAR EN LA ENFERMEDAD TROMBOEMBÓLICA VENOSA

EMSN García, NC Revuelta, ÁR Calavia, CV Puerta - capitulodeflebologia.org
Las heparinas de bajo peso molecular (HBPM) se emplean en la profilaxis de la
enfermedad tromboembólica venosa (ETEV) y en el tratamiento de la trombosis venosa …